Devyser Diagnostics (DVYSR) Q4 2025 earnings summary

Executive summary

• Achieved record quarterly sales of SEK 72 million in Q4 2025 and full-year sales of SEK 250.5 million, up 15.5% year-over-year or 20.2% in local currencies, driven by growth across all segments.

• EBIT reached SEK 18 million in Q4 (25% margin), with full-year EBIT at SEK 10.1 million (4% margin), marking the first full year of positive operating profit after a previous loss.

• Cash position at year-end was SEK 77.5 million, with positive operating cash flow and no debt.

• Strategic focus on profitable growth, cost control, innovation, and expansion through new product launches, acquisitions, and key partnerships.

• No dividend proposed for 2025.

Financial highlights

• Q4 revenue was SEK 72 million, up 12.1% year-over-year; full-year revenue reached SEK 250.5 million, up 15.5% (20.2% FX adjusted).

• Gross margin for Q4 was 79.5%; full-year gross margin was 80.6%, above target.

• Q4 EBIT was SEK 18 million; full-year EBIT was SEK 10.1 million, compared to -SEK 62 million last year.

• Operating cash flow was SEK 12 million in Q4 and SEK 8 million for the full year.

• Earnings per share for Q4 were SEK 0.82; full-year EPS SEK -0.51.

Outlook and guidance

• Focus on capitalizing on launched products, maintaining cost structure, and investing in commercial organization as growth continues.

• Anticipate continued growth in the U.S. and Europe, with expansion in Spain and Italy and gradual reduction in quarterly sales lumpiness.

• Submission of supplementary data to MolDX planned after summer, with a 60-day review period; FDA application for Accept cfDNA study targeted for 2028.